Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 15, 2014No Cases of Moderate or Severe Paravalvular Aortic Regurgitation at One Year
New data from the Boston Scientific (NYSE: BSX) clinical trial program of the Lotus™ Valve System continue to demonstrate strong performance as a less invasive treatment for patients with severe...
-
Sep 10, 2014Data Will Focus on Areas of Significant Unmet Patient Need, Including Coronary Artery Disease and Aortic Valve Disease
Beginning Saturday, Boston Scientific Corporation (NYSE: BSX) will present data that reinforce the company's commitment to advancing science for life and to developing innovative therapies in...
-
Sep 3, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Bank of America Merrill Lynch Global Healthcare Conference on September 17, 2014 in London, England. Michael...
-
Sep 2, 2014
Boston Scientific Corporation (NYSE: BSX) closed on its previously announced agreement to purchase the Interventional business of Bayer AG. The acquisition enhances the ability of Boston...
-
Aug 30, 2014Phase II feasibility trial provides first randomized sham-controlled data using vagus nerve stimulation to treat heart failure
Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical...
-
Aug 25, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Morgan Stanley Global Healthcare Conference on September 8 in New York, NY. Mike Mahoney, chief executive officer, and
-
Aug 19, 2014Companies Reach Agreement to Develop a New and Differentiated FFR Guidewire and Next Generation Boston Scientific Rotablator™ RotaWire™
Boston Scientific Corporation (NYSE: BSX) and ASAHI INTECC (Securities Code 7747, Second Section, Tokyo and Nagoya Stock Exchange) have formalized plans to develop a new, differentiated fractional...
-
Jul 24, 2014
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.873 billion during the second quarter ended June 30, 2014, compared to the company's guidance range for the quarter of $1.840 to...
-
Jul 23, 2014Innovative Technology Adds To Company's Leading Portfolio of Treatment Options for Coronary Artery Disease
Continuing to advance the development of innovative treatment options for coronary artery disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European market...
-
Jul 22, 2014Easy to Use Imaging System to Support Planned Intravascular Ultrasound and Fractional Flow Reserve Products
Boston Scientific Corporation (NYSE: BSX) has initiated full commercial launch of the new POLARIS™ Imaging System. This system will support the Boston Scientific family of intravascular...
-
Jul 21, 2014Advanced Bare-Metal Stent Provides Additional Treatment Option for Interventional Cardiologists and Patients
Boston Scientific Corporation (NYSE: BSX) has received FDA approval for the REBEL™ Platinum Chromium Coronary Stent System, the company's latest generation bare-metal stent for the treatment of...
-
Jul 14, 2014European Launch Means Physicians Can Now Choose From Three Available Valve Sizes To Match Patient Anatomy More Precisely
Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European commercial launch of its new 25 mm Lotus™ Transcatheter Aortic Valve Implantation (TAVI) System,...
-
Jul 14, 2014Innovative Technology Strengthens Company's Leading Portfolio of Solutions for Peripheral Vascular Disease
Demonstrating its continued leadership in the development of innovative solutions for peripheral vascular disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Ranger™...
-
Jul 1, 2014
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results, business highlights and outlook for the second quarter ended June 30, 2014 on Thursday,...
-
Jun 11, 2014Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent...
-
Jun 10, 2014Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
-
Jun 4, 2014
Boston Scientific Corporation (NYSE: BSX) has initiated the RESPOND Post Market Registry to assess real world performance of the Lotus™ Valve System. The RESPOND Registry will collect data on...
-
Jun 3, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo 2014 Healthcare Conference on June 17 in Boston, MA. Dan Brennan, executive vice president and chief...
-
Jun 3, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs 35th Annual Global Healthcare Conference on June 10 in Rancho Palos Verdes, CA. David Pierce, senior vice...
-
May 21, 2014Only 1.1 Percent of Patients Experienced Moderate Paravalvular Aortic Regurgitation; No Severe Cases Occurred
Further validating its advanced transcatheter aortic valve implantation (TAVI) technology, the Boston Scientific Corporation (NYSE: BSX) Lotus™ Valve System continued to demonstrate impressive...
-
May 21, 2014EVOLVE Study Data Presented Today at EuroPCR 2014 Also Demonstrate Excellent Safety Profile
Boston Scientific Corporation (NYSE: BSX) reported positive three-year follow-up data for the EVOLVE clinical trial, comparing the safety and performance of the SYNERGY™ Everolimus-Eluting...
-
May 15, 2014Boston Scientific Offers World Class Endoscopy Training at its Paris Institute for Advancing ScienceBoston Scientific Reinforces Its Commitment to Global Education and Innovation
Boston Scientific Corporation (NYSE: BSX) celebrated the opening of a new facility dedicated to endoscopy training within its Institute for Advancing Science in Paris. The ceremony included major...
-
May 15, 2014Acquisition Expected to Strengthen Peripheral Interventions Business and Accelerate Growth in Peripheral Atherectomy and Thrombectomy Categories
In a move to expand significantly its portfolio of leading solutions for peripheral interventions, Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire the...
-
May 10, 2014PREDICt-RM Collaborative Study between Boston Scientific, American College of Cardiology and Yale University Highlights Improved Outcomes in ICD and CRT-D Patients followed with the LATITUDE™ System
Patients using the Boston Scientific Corporation (NYSE: BSX) LATITUDE™ Remote Patient Management system with wireless telemetry demonstrated significantly lower mortality and fewer...
-
May 8, 2014Boston Scientific Shockless Implant Evaluation (SIMPLE) Study Results Presented at Heart Rhythm 2014, the Heart Rhythm Society's 35th Annual Scientific Sessions
A Boston Scientific Corporation (NYSE: BSX) study demonstrated that outcomes for patients with the company's transvenous implantable cardioverter defibrillators (ICD) who received routine...